0750 GMT - Parkway Life REIT is a "rare jewel" among Singapore REITs, as it offers highly visible, stable and sustainable earnings, DBS Group Research analysts write in a note. The REIT owns three private hospitals in Singapore, holding the majority of the market share, they say. Its recent unit-price correction implies an attractive forward 2026 yield of 5.0%, they add. A cross-check across four major valuation metrics suggests an overcorrection, positioning the units for a rebound, the analysts say. DBS raises the REIT's target price to S$4.80 from S$4.50 while maintaining a buy rating. Units are last 0.8% higher at S$3.73. (amanda.lee@wsj.com)
(END) Dow Jones Newswires
November 26, 2024 02:50 ET (07:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。